Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04703244 · ClinicalTrials.gov registry record
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
A clinical trial of Breast Cancer and Residual, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 999
- Enrollment target
- 1
- Study location
NCT04703244: Recruiting study of Breast Cancer and Residual, sponsored by Mayo Clinic.
NCT04703244 is a study of Breast Cancer and Residual that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 999 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04703244, a study of Breast Cancer and Residual, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 999 participants
- Enrollment target
- 1
- Study location
Study Summary
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
Conditions Studied
Interventions
- PROCEDURE chemotherapy or endocrine therapy for breast cancer
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2042-01-15 |
What NCT04703244 shows while recruiting
NCT04703244 is an observational study that tracks outcomes without assigning an intervention. The registered 999 participants enrollment target is mid-sized for trials with a published cap, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which chemotherapy or endocrine therapy for breast cancer is the first listed.
NCT04703244 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04703244 about?
NCT04703244 is a clinical study titled "Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer". Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
What is the current status of trial NCT04703244?
This trial is currently recruiting. The enrollment target is 999 participants. The study started on 2021-01-13. Estimated completion is 2042-01-15.
What conditions does trial NCT04703244 study?
This clinical trial studies the following conditions: Breast Cancer, Residual.
What interventions are being tested in trial NCT04703244?
The interventions under investigation include: chemotherapy or endocrine therapy for breast cancer (PROCEDURE).
Who is sponsoring clinical trial NCT04703244?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04703244 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04703244's enrollment target sits among peer trials
999 129th of 1224 higher than 1,096 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI